The first patient has been dosed in the phase 2 DR:EAM clinical trial assessing OTT166 for the treatment of diabetic retinopathy, according to a press release from OcuTerra Therapeutics.
The multicenter, randomized, double-masked trial will include 200 adult subjects with moderately severe to severe nonproliferative diabetic retinopathy or mild proliferative diabetic retinopathy with minimal vision loss. They will be treated with daily topical OTT166 or placebo for 24 weeks.
The trial will investigate safety and efficacy, including the percentage of participants who have a two-step or greater